Z Wu1, S Zhang1, L Zhou1, J Cai2, J Tan2, X Gao2, Z Zeng1, D Li3. 1. Department of Hepatobiliary Disease, Fuzhou General Hospital (Donfang Hospital), Xiamen University, Fuzhou, China. 2. Organ Transplant Institute, Fuzhou General Hospital (Dongfang Hospital), Xiamen University, Fuzhou, China. 3. Department of Hepatobiliary Disease, Fuzhou General Hospital (Donfang Hospital), Xiamen University, Fuzhou, China. Electronic address: dongliangli93@163.com.
Abstract
OBJECTIVE: To investigate the thromboembolism induced by blood-mediated inflammatory reactions against infused cells during the clinical application of stem cells. METHODS: Two patients with renal transplantation and chronic kidney disease, respectively, experienced thromboembolism after umbilical cord mesenchymal stem cell (UCMSC) infusion. The clinical manifestations and the laboratory test results were collected and analyzed. RESULTS: The patients received stem cell infusion through the peripheral veins and presented with a swollen and painful forearm postinfusion. Doppler ultrasound showed venous clots at the proximal end of the puncture site. Urokinase and warfarin were used for thrombolytic therapy. The swelling and pain were relieved and cured. CONCLUSION: Safety concerns are still a primary hurdle for stem cell therapy, and thromboembolism as a critical complication should be prevented appropriately.
OBJECTIVE: To investigate the thromboembolism induced by blood-mediated inflammatory reactions against infused cells during the clinical application of stem cells. METHODS: Two patients with renal transplantation and chronic kidney disease, respectively, experienced thromboembolism after umbilical cord mesenchymal stem cell (UCMSC) infusion. The clinical manifestations and the laboratory test results were collected and analyzed. RESULTS: The patients received stem cell infusion through the peripheral veins and presented with a swollen and painful forearm postinfusion. Doppler ultrasound showed venous clots at the proximal end of the puncture site. Urokinase and warfarin were used for thrombolytic therapy. The swelling and pain were relieved and cured. CONCLUSION: Safety concerns are still a primary hurdle for stem cell therapy, and thromboembolism as a critical complication should be prevented appropriately.
Authors: Henry Caplan; Scott D Olson; Akshita Kumar; Mitchell George; Karthik S Prabhakara; Pamela Wenzel; Supinder Bedi; Naama E Toledano-Furman; Fabio Triolo; Julian Kamhieh-Milz; Guido Moll; Charles S Cox Journal: Front Immunol Date: 2019-07-31 Impact factor: 7.561
Authors: Louise Coppin; Mustapha Najimi; Julie Bodart; Marie-Sophie Rouchon; Patrick van der Smissen; Stéphane Eeckhoudt; Géraldine Dahlqvist; Diego Castanares-Zapatero; Mina Komuta; Sanne L Brouns; Constance C Baaten; Johan W M Heemskerk; Sandrine Horman; Nathalie Belmonte; Etienne Sokal; Xavier Stéphenne Journal: Cells Date: 2019-08-07 Impact factor: 6.600